comparemela.com

Page 3 - Matthew Pillar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

What s True Of Mice ≠ What s True Of Men

As ATMPs advance, scientists are calling out the limited value of mouse models in pharmacological re-search and testing. LIfT Biosciences’.

United kingdomAlex blythMatthew pillarBioprocess online

Navigating A Clinical Hold

FDA-ordered clinical holds are on the rise, and biologics IND are driving them. Immunome CEO Purnanand Sarma, Ph.D. shares his take on the role of.

Purnanand sarmaMichael yeeMatthew pillarBioprocess onlineClinical biopharmaImmunome president

The Coming Wave Of Radio(bio)pharmaceuticals

Convergent Therapeutics is bullish on the combination of radioisotopes and antibodies to direct radiation directly to cancer cells. As enabling.

Philip kantoffPluvicto luAlex brownDepartment of energyDevelopment burgeonCardinal healthHarvard medical school professorMemorial sloan kettering cancer centerConvergent therapeuticsa brown university medicalDana farber cancer instituteMatthew pillarBioprocess onlineHarvard medical school professor emeritusConvergent therapeuticsconvergentNew product planningGlobal oncology

Formulation Alternatives Looking Beyond Parenteral Biologics

2022 could be a breakout year for oral, intranasal, and inhalable biologics. As innovative biopharma companies clear formulation, stability, and.

United statesGrand viewAugmenta bioworksKartik chandranSean tuckerinA celltrion intractTed rossSean tuckerDevelopment agreementUniversity of georgia drAlbert einstein college of medicineView researchUniversity of pennsylvania drCoherent market researchGlobal industry analysts incMatthew pillar

Competitive Differentiation In A Crowded Market

When is it time for an emerging biopharma company to truly emerge, and what goes into its competitive positioning? Biopharma industry veteran Allan.

Allan shawElizabeth holmes theranosMatthew pillarBioprocess onlineBiopharma special advisorBoard memberclearly

vimarsana © 2020. All Rights Reserved.